Corcept Therapeutics Inc (CORT)
50.07
+2.45
(+5.14%)
USD |
NASDAQ |
Nov 04, 16:00
50.07
0.00 (0.00%)
After-Hours: 20:00
Corcept Therapeutics Enterprise Value: 4.609B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 4.609B |
| October 31, 2024 | 4.751B |
| October 30, 2024 | 4.533B |
| October 29, 2024 | 4.671B |
| October 28, 2024 | 4.684B |
| October 25, 2024 | 4.573B |
| October 24, 2024 | 4.569B |
| October 23, 2024 | 4.655B |
| October 22, 2024 | 4.742B |
| October 21, 2024 | 4.762B |
| October 18, 2024 | 4.829B |
| October 17, 2024 | 4.559B |
| October 16, 2024 | 4.569B |
| October 15, 2024 | 4.524B |
| October 14, 2024 | 4.363B |
| October 11, 2024 | 4.376B |
| October 10, 2024 | 4.357B |
| October 09, 2024 | 4.430B |
| October 08, 2024 | 4.413B |
| October 07, 2024 | 4.296B |
| October 04, 2024 | 4.376B |
| October 03, 2024 | 4.335B |
| October 02, 2024 | 4.421B |
| October 01, 2024 | 4.515B |
| September 30, 2024 | 4.465B |
| Date | Value |
|---|---|
| September 27, 2024 | 4.117B |
| September 26, 2024 | 4.049B |
| September 25, 2024 | 3.972B |
| September 24, 2024 | 4.125B |
| September 23, 2024 | 4.015B |
| September 20, 2024 | 3.942B |
| September 19, 2024 | 3.803B |
| September 18, 2024 | 3.944B |
| September 17, 2024 | 3.676B |
| September 16, 2024 | 3.547B |
| September 13, 2024 | 3.509B |
| September 12, 2024 | 3.258B |
| September 11, 2024 | 3.242B |
| September 10, 2024 | 3.187B |
| September 09, 2024 | 3.153B |
| September 06, 2024 | 3.119B |
| September 05, 2024 | 3.090B |
| September 04, 2024 | 3.144B |
| September 03, 2024 | 3.107B |
| August 30, 2024 | 3.215B |
| August 29, 2024 | 3.199B |
| August 28, 2024 | 3.126B |
| August 27, 2024 | 3.149B |
| August 26, 2024 | 3.184B |
| August 23, 2024 | 3.162B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
882.59M
Minimum
Mar 16 2020
4.829B
Maximum
Oct 18 2024
2.144B
Average
2.097B
Median
Enterprise Value Benchmarks
| ADMA Biologics Inc | 4.558B |
| Akebia Therapeutics Inc | 353.92M |
| Bioventus Inc | 1.273B |
| Alnylam Pharmaceuticals Inc | 33.57B |
| Catalyst Pharmaceuticals Inc | 2.222B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 47.21M |
| Revenue (Quarterly) | 182.55M |
| Total Expenses (Quarterly) | 135.95M |
| EPS Diluted (Quarterly) | 0.41 |
| Gross Profit Margin (Quarterly) | 98.43% |
| Profit Margin (Quarterly) | 25.86% |
| Earnings Yield | 2.52% |
| Operating Earnings Yield | 2.57% |
| Normalized Earnings Yield | 2.516 |